Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany

In Germany, a mandatory early benefit assessment (EBA) by the Federal Joint Committee (G-BA) is required for reimbursement of new marketing-authorised medicines. Additional benefit is based on patient-relevant endpoints in mortality, morbidity and health-related quality of life (HRQoL). We aimed to compare endpoints and related benefit categories used in marketing authorisation to those considered by G-BA in the field of oncology.

MoreLess

Year of publication:	2014
Authors:	Ruof, Jörg ; Knoerzer, Dietrich ; Dünne, Anja-Alexandra ; Dintsios, Charalabos-Markos ; Staab, Thomas ; Schwartz, Friedrich Wilhelm
Published in:	Health Policy. - Elsevier, ISSN 0168-8510. - Vol. 118.2014, 2, p. 242-254
Publisher:	Elsevier
Subject:	(Early) benefit assessment \| Patient-relevant endpoints \| Mortality \| Morbidity \| Health-related quality of life \| Oncology

More details

Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://ebvufind01.dmz1.zbw.eu/10011116913